FR2947181B1 - Composition de facteur vii - Google Patents

Composition de facteur vii

Info

Publication number
FR2947181B1
FR2947181B1 FR0954390A FR0954390A FR2947181B1 FR 2947181 B1 FR2947181 B1 FR 2947181B1 FR 0954390 A FR0954390 A FR 0954390A FR 0954390 A FR0954390 A FR 0954390A FR 2947181 B1 FR2947181 B1 FR 2947181B1
Authority
FR
France
Prior art keywords
factor vii
vii composition
composition
factor
vii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR0954390A
Other languages
English (en)
French (fr)
Other versions
FR2947181A1 (fr
Inventor
Annie Bardat
Cornelius Pompe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB Biotechnologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0954390A priority Critical patent/FR2947181B1/fr
Application filed by LFB Biotechnologies SAS filed Critical LFB Biotechnologies SAS
Priority to ES10734272.7T priority patent/ES2550269T3/es
Priority to PL15175122T priority patent/PL2985033T3/pl
Priority to EP15175122.9A priority patent/EP2985033B3/fr
Priority to PCT/FR2010/051229 priority patent/WO2010149907A1/fr
Priority to US13/377,680 priority patent/US9029316B2/en
Priority to ES15175122T priority patent/ES2725449T7/es
Priority to EP10734272.7A priority patent/EP2445516B1/fr
Priority to BRPI1010707A priority patent/BRPI1010707A2/pt
Priority to CN201510137928.9A priority patent/CN105106943A/zh
Priority to CN201080028582.4A priority patent/CN102458455B/zh
Priority to TR2019/06145T priority patent/TR201906145T4/tr
Priority to AU2010264369A priority patent/AU2010264369B2/en
Priority to JP2012516820A priority patent/JP5706888B2/ja
Priority to KR1020127002102A priority patent/KR101468115B1/ko
Priority to DK15175122.9T priority patent/DK2985033T6/da
Priority to PL10734272T priority patent/PL2445516T3/pl
Priority to DK10734272.7T priority patent/DK2445516T3/en
Priority to CA2764779A priority patent/CA2764779C/fr
Priority to ARP100102255A priority patent/AR077234A1/es
Publication of FR2947181A1 publication Critical patent/FR2947181A1/fr
Priority to IL216872A priority patent/IL216872A/en
Application granted granted Critical
Publication of FR2947181B1 publication Critical patent/FR2947181B1/fr
Priority to JP2015038948A priority patent/JP2015134795A/ja
Priority to US14/687,499 priority patent/US9358275B2/en
Priority to US15/165,786 priority patent/US9968662B2/en
Priority to JP2017001018A priority patent/JP2017081978A/ja
Priority to FR23C1001C priority patent/FR23C1001I2/fr
Priority to NL301213C priority patent/NL301213I2/nl
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FR0954390A 2009-06-26 2009-06-26 Composition de facteur vii Active FR2947181B1 (fr)

Priority Applications (27)

Application Number Priority Date Filing Date Title
FR0954390A FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii
DK15175122.9T DK2985033T6 (da) 2009-06-26 2010-06-18 Faktor VII-sammensætning
EP15175122.9A EP2985033B3 (fr) 2009-06-26 2010-06-18 Composition de facteur vii
PCT/FR2010/051229 WO2010149907A1 (fr) 2009-06-26 2010-06-18 Composition de facteur vii
US13/377,680 US9029316B2 (en) 2009-06-26 2010-06-18 Factor VII composition
ES15175122T ES2725449T7 (es) 2009-06-26 2010-06-18 Composición de factor VII
EP10734272.7A EP2445516B1 (fr) 2009-06-26 2010-06-18 Composition de facteur vii
BRPI1010707A BRPI1010707A2 (pt) 2009-06-26 2010-06-18 composição farmacêutica, processo para o preparo da mesma, processo para o preparo de uma formulação injetável e formulação injetável
CN201510137928.9A CN105106943A (zh) 2009-06-26 2010-06-18 因子vii组合物
CN201080028582.4A CN102458455B (zh) 2009-06-26 2010-06-18 因子vii组合物
TR2019/06145T TR201906145T4 (tr) 2009-06-26 2010-06-18 Faktör VII bileşimi.
AU2010264369A AU2010264369B2 (en) 2009-06-26 2010-06-18 Factor VII composition
JP2012516820A JP5706888B2 (ja) 2009-06-26 2010-06-18 第ｖｉｉ因子組成物
KR1020127002102A KR101468115B1 (ko) 2009-06-26 2010-06-18 제ⅶ인자 조성물
ES10734272.7T ES2550269T3 (es) 2009-06-26 2010-06-18 Composición de factor VII
PL10734272T PL2445516T3 (pl) 2009-06-26 2010-06-18 Kompozycja czynnika VII
PL15175122T PL2985033T3 (pl) 2009-06-26 2010-06-18 Kompozycja czynnika VII
CA2764779A CA2764779C (fr) 2009-06-26 2010-06-18 Composition de facteur vii
DK10734272.7T DK2445516T3 (en) 2009-06-26 2010-06-18 Factor vii composition
ARP100102255A AR077234A1 (es) 2009-06-26 2010-06-25 Composicion de factor vii. procedimiento para prepararla
IL216872A IL216872A (en) 2009-06-26 2011-12-08 Factor vii preparation
JP2015038948A JP2015134795A (ja) 2009-06-26 2015-02-27 第ｖｉｉ因子組成物
US14/687,499 US9358275B2 (en) 2009-06-26 2015-04-15 Factor VII composition
US15/165,786 US9968662B2 (en) 2009-06-26 2016-05-26 Factor VII composition
JP2017001018A JP2017081978A (ja) 2009-06-26 2017-01-06 第ｖｉｉ因子組成物
FR23C1001C FR23C1001I2 (fr) 2009-06-26 2023-01-10 Composition de facteur vii
NL301213C NL301213I2 (nl) 2009-06-26 2023-01-16 eptacog beta

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0954390A FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii

Publications (2)

Publication Number Publication Date
FR2947181A1 FR2947181A1 (fr) 2010-12-31
FR2947181B1 true FR2947181B1 (fr) 2012-05-04

Family

ID=41620211

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0954390A Active FR2947181B1 (fr) 2009-06-26 2009-06-26 Composition de facteur vii
FR23C1001C Active FR23C1001I2 (fr) 2009-06-26 2023-01-10 Composition de facteur vii

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR23C1001C Active FR23C1001I2 (fr) 2009-06-26 2023-01-10 Composition de facteur vii

Country Status (17)

Country Link
US (3) US9029316B2 (enExample)
EP (2) EP2445516B1 (enExample)
JP (3) JP5706888B2 (enExample)
KR (1) KR101468115B1 (enExample)
CN (2) CN102458455B (enExample)
AR (1) AR077234A1 (enExample)
AU (1) AU2010264369B2 (enExample)
BR (1) BRPI1010707A2 (enExample)
CA (1) CA2764779C (enExample)
DK (2) DK2985033T6 (enExample)
ES (2) ES2725449T7 (enExample)
FR (2) FR2947181B1 (enExample)
IL (1) IL216872A (enExample)
NL (1) NL301213I2 (enExample)
PL (2) PL2985033T3 (enExample)
TR (1) TR201906145T4 (enExample)
WO (1) WO2010149907A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1711513T3 (pl) 2003-12-01 2014-12-31 Novo Nordisk Healthcare Ag Nanofiltracja roztworów czynnika vii w celu usunięcia wirusów
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
PH12013501365A1 (en) 2010-12-30 2013-09-16 Laboratoire Francais Du Fractionnment Et Des Biotechnologies Glycols as pathogen inactivating agents
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
US20180169297A1 (en) 2015-06-12 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Injectable composition of factor vii and fillers
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
TW202444744A (zh) * 2016-07-11 2024-11-16 以色列商歐科生物製品有限公司 長效型凝血因子及其生產方法
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
CN117860874B (zh) * 2024-03-12 2024-07-02 正大天晴药业集团南京顺欣制药有限公司 重组人凝血因子VIIa的药物组合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
JP3543144B2 (ja) * 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
WO2001012653A1 (en) * 1999-08-17 2001-02-22 Novo Nordisk A/S Stabilisation of freeze-dried cake
AU2001254624A1 (en) * 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
PL207018B1 (pl) 2002-06-21 2010-10-29 Novo Nordisk Helth Care Ag Kompozycja farmaceutyczna, sposób przygotowania stabilnego polipeptydu czynnika VII i zastosowanie polipeptydu czynnika VII
WO2004111242A1 (en) * 2003-06-19 2004-12-23 Maxygen Holdings Ltd. FACTOR VII OR VIIa GLA DOMAIN VARIANTS
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
RU2388460C2 (ru) * 2003-08-14 2010-05-10 Ново Нордиск Хелс Кеа Аг Жидкая водная фармацевтическая композиция, содержащая полипептид фактора vii
JP2008531525A (ja) * 2005-02-24 2008-08-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチド製剤を安定化する化合物
KR101364003B1 (ko) * 2005-04-28 2014-02-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 활성화된 제ｖｉｉ 인자 폴리펩타이드를 포함하는 밀폐용기와 이의 제조방법 및, 키트와 키트의 사용방법
EP1919498A2 (en) * 2005-08-26 2008-05-14 Maxygen Holdings Ltd. Liquid factor vii composition
FR2894831B1 (fr) * 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
WO2008078189A2 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
CN104887620A (zh) * 2007-05-02 2015-09-09 诺沃—诺迪斯克保健股份有限公司 包括芳香族防腐剂和抗氧化剂的高浓度因子vii多肽制剂
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii

Also Published As

Publication number Publication date
JP2012530770A (ja) 2012-12-06
BRPI1010707A2 (pt) 2016-03-15
US20120087908A1 (en) 2012-04-12
KR101468115B1 (ko) 2014-12-03
ES2725449T3 (es) 2019-09-24
JP2015134795A (ja) 2015-07-27
EP2985033B1 (fr) 2019-03-20
CN102458455A (zh) 2012-05-16
CA2764779C (fr) 2015-09-29
CN105106943A (zh) 2015-12-02
FR23C1001I2 (fr) 2025-03-28
AR077234A1 (es) 2011-08-10
US9968662B2 (en) 2018-05-15
JP5706888B2 (ja) 2015-04-22
EP2445516B1 (fr) 2015-08-12
US9358275B2 (en) 2016-06-07
US20150216951A1 (en) 2015-08-06
WO2010149907A1 (fr) 2010-12-29
IL216872A (en) 2017-07-31
EP2985033A1 (fr) 2016-02-17
EP2985033B3 (fr) 2022-10-26
FR2947181A1 (fr) 2010-12-31
AU2010264369A1 (en) 2012-01-19
AU2010264369B2 (en) 2013-06-27
KR20120047918A (ko) 2012-05-14
CN102458455B (zh) 2015-04-08
PL2985033T3 (pl) 2019-08-30
DK2985033T6 (da) 2022-11-07
FR23C1001I1 (fr) 2023-03-10
ES2550269T3 (es) 2015-11-05
US9029316B2 (en) 2015-05-12
EP2445516A1 (fr) 2012-05-02
TR201906145T4 (tr) 2019-05-21
NL301213I1 (enExample) 2023-01-18
NL301213I2 (nl) 2023-12-14
DK2985033T3 (da) 2019-06-17
CA2764779A1 (fr) 2010-12-29
JP2017081978A (ja) 2017-05-18
PL2445516T3 (pl) 2015-12-31
DK2445516T3 (en) 2015-10-19
US20160271233A1 (en) 2016-09-22
IL216872A0 (en) 2012-02-29
ES2725449T7 (es) 2022-12-20

Similar Documents

Publication Publication Date Title
FR23C1001I2 (fr) Composition de facteur vii
SMT201600307B (it) Composizione liposomiale
BRPI1013588A2 (pt) composição
BRPI1015474A2 (pt) composição
BRPI1010709A2 (pt) composição nutricional
BRPI1013335A2 (pt) composição compósita
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
EP2488022A4 (en) Compositions
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
FR2942627B1 (fr) Composition de graisse
UY33161A (es) Composiciones plaguicidas
BRPI1008774A2 (pt) espiroamida substituída
DOP2011000396A (es) Composiciones novedosas
BRPI1010690A2 (pt) composições
EP2549487A4 (en) NANO INK COMPOSITIONS
EP2516011A4 (en) CARRIER COMPOSITION
BRPI1005318A2 (pt) composição
EP2394634A4 (en) COMPOSITION CONTAINING HESPERIDINE
BR112012003604A2 (pt) composição de revestimento
EP2479211A4 (en) FLUOR RUBBER COMPOSITION
EP2413905A4 (en) FORMULATION
EP2448583A4 (en) Substituted 4-hydroxypyrimidine-5-carboxamides
EP2484354A4 (en) ANTIOXIDANT COMPOSITION
BRPI0917290A2 (pt) composição imunológica
BR112012002281A2 (pt) composicoes poliofinicas

Legal Events

Date Code Title Description
TP Transmission of property

Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES , FR

Effective date: 20130829

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

CA Change of address

Effective date: 20220816

RM Correction of a material error

Effective date: 20221110

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17